• Explore /
  • Poster
  • / HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.

HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.

Abstract Poster

Authors

null

Jason Brown

Division of Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH

Jason Brown , Hristos Z. Kaimakliotis , William Kevin Kelly , Vikki Ammons , Joel Picus , Radhika Walling , Neda Hashemi-Sadraei , Pingfu Fu , Seunghee P Margevicius , Nabil Adra , Jorge A. Garcia , Rana R. McKay , Christopher J. Hoimes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02365766

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 448)

DOI

10.1200/JCO.2023.41.6_suppl.448

Abstract #

448

Poster Bd #

C4

Abstract Disclosures

Similar Posters

First Author: Haojie Li

First Author: Ali Raza Khaki

First Author: MInoru Kato

First Author: Rohit K. Jain